4.6 Article

CD8+ T Cells Expressing an HLA-DR1 Chimeric Antigen Receptor Target Autoimmune CD4+ T Cells in an Antigen-Specific Manner and Inhibit the Development of Autoimmune Arthritis

Journal

JOURNAL OF IMMUNOLOGY
Volume 208, Issue 1, Pages 16-26

Publisher

AMER ASSOC IMMUNOLOGISTS
DOI: 10.4049/jimmunol.2100643

Keywords

-

Categories

Funding

  1. National Institutes of Health, National Institute of Arthritis and Musculoskeletal and Skin Diseases Grant [AR071633]
  2. U.S. Department of Veterans Affairs

Ask authors/readers for more resources

By engineering an HLA-DR1 chimeric Ag receptor (CAR), researchers have produced CD8(+) CAR T cells that specifically target CD4(+) T cells in an Ag-specific manner. These CAR T cells have shown the ability to inhibit the development of autoimmune arthritis in a mouse model, suggesting their potential as a highly specific therapeutic approach for autoimmune disease.
Ag-specific immunotherapy is a long-term goal for the treatment of autoimmune diseases; however developing a means of therapeutically targeting autoimmune T cells in an Ag-specific manner has been difficult. Through the engineering of an HLA-DR1 chimeric Ag receptor (CAR), we have produced CD8(+) CAR T cells that target CD4(+) T cells in an Ag-specific manner and tested their ability to inhibit the development of autoimmune arthritis in a mouse model. The DR1 CAR molecule was engineered to contain CD3f activation and CD28 signaling domains and a covalently linked autoantigenic peptide from type II collagen (CII; DR1-CII) to provide specificity for targeting the autoimmune T cells. Stimulation of the DR1-CII CAR T cells by an anti-DR Ab induced cytokine production, indicating that the DR1-CAR functions as a chimeric molecule. In vitro CTL assays using cloned CD4(+) T cells as target cells demonstrated that the DR1-CII CART cells efficiently recognize and kill CD4(+) T cells that are specific for the CII autoantigen. The CTL function was highly specific, as no killing was observed using DR1-restricted CD4(+) T cells that recognize other Ags. When B6.DR1 mice, in which autoimmune arthritis had been induced, were treated with the DR1-CII CAR T cells, the CII-specific autoimmune CD4+ T cell response was significantly decreased, autoantibody production was suppressed, and the incidence and severity of the autoimmune arthritis was diminished. These data demonstrate that HLA-DR CAR T cells have the potential to provide a highly specific therapeutic approach for the treatment of autoimmune disease.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available